Key facts
- Notable investors include Arbelon Holdings.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cogniguard
- ·The full record, as it builds
Funding rounds
No funding rounds for Cogniguard are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cogniguard
Developer of a non-invasive neuromodulation platform designed to treat neurological disorders, including early-stage Alzheimer's disease. The company offers physician-prescribed, sleep-synchronised vagus nerve stimulation systems, regulator-certified medical devices, proprietary stimulation protocols, clinical validation, and cloud-enabled patient monitoring infrastructure, enabling patients and healthcare providers to manage neurological conditions in outpatient settings with improved therapeutic oversight.
- Sector
- Healthcare
- HQ
- Lodz, Poland
- Founded
- 2025
- Employees
- 11
- Website
- cogniguard.com/
- Ownership
- Privately Held (backing)
Cogniguard doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cogniguard shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cogniguard in its N-PORT filings yet. We sweep new filings monthly.